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Abstract
The genetic etiology of sporadic neuroblastoma is still largely obscure. In a genome-wide association study,
we identiﬁed single-nucleotide polymorphisms (SNP) associated with neuroblastoma at the CASC15, BARD1,
LMO1, DUSP12, HSD17B12, HACE1, and LIN28B gene loci, but these explain only a small fraction of
neuroblastoma heritability. Other neuroblastoma susceptibility genes are likely hidden among signals
discarded by the multiple testing corrections. In this study, we evaluated eight additional genes selected
as candidates for further study based on proven involvement in neuroblastoma differentiation. SNPs at these
candidate genes were tested for association with disease susceptibility in 2,101 cases and 4,202 controls, with
the associations found replicated in an independent cohort of 459 cases and 809 controls. Replicated
associations were further studied for cis-effect using gene expression, transient overexpression, silencing,
and cellular differentiation assays. The neuroﬁlament gene NEFL harbored three SNPs associated with
neuroblastoma (rs11994014: Pcombined ¼ 0.0050; OR, 0.88; rs2979704: Pcombined ¼ 0.0072; OR, 0.87; rs1059111:
Pcombined ¼ 0.0049; OR, 0.86). The protective allele of rs1059111 correlated with increased NEFL expression.
Biologic investigations showed that ectopic overexpression of NEFL inhibited cell growth speciﬁcally in
neuroblastoma cells carrying the protective allele. NEFL overexpression also enhanced differentiation and
impaired the proliferation and anchorage-independent growth of cells with protective allele and basal NEFL
expression, while impairing invasiveness and proliferation of cells homozygous for the risk genotype.
Clinically, high levels of NEFL expression in primary neuroblastoma specimens were associated with better
overall survival (P¼ 0.03; HR, 0.68). Our results show that common variants of NEFL inﬂuence neuroblastoma
susceptibility and they establish that NEFL expression inﬂuences disease initiation and progression. Cancer
Res; 74(23); 6913–24. 2014 AACR.
Introduction
Neuroblastoma is a cancer of the sympathetic nervous
system. It is the most frequent solid tumor of early childhood
with a remarkable variation in clinical presentation ranging
from favorable localized tumors that can spontaneously
regress to metastatic disease that shows relentless progres-
sion (1). Despite intensive therapies, the survival rate for the
patient subgroup with the most aggressive form remains
approximately 40%. While familial neuroblastoma, which
accounts for approximately 1% of cases, is in large propor-
tion due to mutations in the ALK gene (2), the genetic bases
of sporadic neuroblastoma remain largely unknown (3). Our
ongoing genome-wide association study (GWAS) has dem-
onstrated that genetic variants within the CASC15, BARD1,
LMO1, DUSP12, HSD17B12, HACE1, and LIN28B genes (4–8)
are strongly associated with neuroblastoma in North Amer-
ican patients of European descent, and each of these asso-
ciations have been replicated in an independent Italian
population (9). However, these risk variants only explain a
small proportion of neuroblastoma heritability and addi-
tional predisposing variants to neuroblastoma remain to be
discovered.
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The remaining genetic risk is probably made up by a
combination of common variants with verymodest effect sizes
and by rare variantswith stronger effects. Someof the common
genetic risk variants are probably hidden among signals dis-
carded by themultiple testing correctionneeded in the analysis
of GWAS data. This multiple testing correction is necessary to
exclude false-positive loci, but simultaneously it discardsmany
true-positive risk loci. Different research strategies have been
proposed (10) for extracting these hidden true-positive loci,
such as increasing the GWAS sample size, performing a meta-
analysis of GWAS datasets, replicating hundreds to thousands
of GWAS signals in a larger cohort, performing imputation and
epistasis analysis, using pathway-based and single nucleotide
polymorphism (SNP)-set enrichment approaches, and others.
Here, to discover new common variants associated with
neuroblastoma, we adopted a strategy based on the selection of
genes with high relevance to neuroblastoma differentiation,
which were identiﬁed in our previous proteomic study (11).
Arrested differentiation of neuroblasts at various stages is a
crucial early event in neuroblastoma pathogenesis, especially
in themore aggressive cases. Indeed, a particular characteristic
of neuroblastic tumors is their broad spectrum of cellular
differentiation, ranging from undifferentiated cells that indi-
cate a poor prognosis to those showing greater differentiation
and predicting a generally favorable outcome (12). This het-
erogeneity suggests that dysregulated differentiation of sym-
pathetic progenitor cells plays a key role in neuroblastoma
pathogenesis. We thus hypothesized that variation in genes
involved in neuroblastic differentiation might predispose to
neuroblastoma development. This hypothesis is supported by
recent research showing that functional alterations of key
regulators of neuron development can induce neuroblastic
malignant transformation (13, 14).
In the present study, we performed a gene-based association
analysis of eight genes recently shown to bemajor regulators of
neuroblastoma differentiation (11). A large cohort of 2,101
patients and 4,202 control subjects was used as discovery set,
whereas an independent population of 459 cases and 809
controls was used as replication set. The results showed a
signiﬁcant association of SNPs within NEFL with neuroblas-
toma risk. Additional in silico and in vitro analyses demon-
strated a functional role of the neuroblastoma-associated SNPs
and indicated that NEFL likely has a role in disease develop-
ment and progression.
Materials and Methods
Study subjects
This study was approved by the Ethics Committee of the
Medical University of Naples and the Children's Hospital of
Philadelphia.
This study included a GWAS dataset of 2,101 neuroblastoma
patients registered through the North American-based Chil-
dren's Oncology Group and 4,202 cancer-free children of self-
reportedCaucasian ancestrywhowere recruited andgenotyped
by theCenter for AppliedGenomics at theChildren'sHospital of
Philadelphia. European American cases and controls have been
described in detail in a previous publication (8). In addition, this
study also included459neuroblastomapatients and809 cancer-
free controls of Italian origin. Additional details and eligibility
criteria for genotyping of both populations are reported in
Supplementary Information. This study was approved by the
Ethics Committee of the Medical University of Naples and the
Children's Hospital of Philadelphia.
Selection of genes involved in neuroblastoma
differentiation
Our previous study has demonstrated that eight proteins are
differentially expressed during neuroblastoma differentiation
by two-dimensional differential in-gel electrophoresis analysis
of the cytosolic and nuclear protein expression patterns of
LAN-5 cells following neuronal differentiating agent all-trans-
retinoic acid treatment (11). The retinoic acid differential
expression patterns of these eight proteins were further val-
idated in three cell lines (LAN-5, SH-SY5Y, and SK-N-BE) by
Western blotting and gene expression (11). This motivated us
to select the genes (EEF1A, EEF2, GNB2, NEFL, PCNA, PRDX2,
SCG2, and VBP1) that encode the eight proteins to be tested for
association with neuroblastoma development (Table 1).
Table 1. Gene-based association analysis in neuroblastoma GWAS dataset (2,101 cases and 4,202
controls)
Gene sets NSNP NSIG ISIG EMP FDR SNPs
EEF1A1 4 0 0 1 1 NS
EEF2 6 0 0 1 1 NS
GNB2 3 0 0 1 1 NS
NEFL 8 4 2 0.0076 0.0304 rs118727jrs169061
PCNA 6 0 0 1 1 NS
PRDX2 2 0 0 1 1 NS
SCG2 7 1 1 0.0037 0.0296 rs4673067
VBP1 0 0 0 1 1 NS
Abbreviations: EMP, empirical gene-based P value; FDR, false discovery rate correction method applied to EMP; ISIG, number of
signiﬁcant also passing LD-criterion; NS, not signiﬁcant; NSIG, total number of SNPs belowP value threshold; NSNP, number of SNPs
in gene and surrounding genomic region (20 kb).
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SNP genotyping
The European American DNA samples were genotyped
using the Illumina Inﬁnium II BeadChip HumanHap550 v1,
v3, and Quad610 arrays according to methods detailed else-
where (8). The quality control analyses for this GWAS dataset
are described in detail elsewhere (8). We analyzed six SNPs of
NEFL (rs196830, rs169061, rs11994014, rs2979704, rs1059111,
and rs3761) in the Italian cohort. The DNA samples were
genotyped using SNP Genotyping Assay on 7900HT Real-time
PCR system (Applied Biosystems). More details on SNP geno-
typing are reported in Supplementary Information.
Gene-based association analysis
The SNP genotypes of each selected gene and surrounding
genomic region (20 kb) were extracted from the GWAS
dataset. The analysis was carried out by using the set-based
test implemented in the PLINK software (15). Brieﬂy, for each
gene, a standard single SNP analysis (case–control association)
is performed. SNPs with P value > 0.05 and/or a Linkage
Disequilibrium (LD) coefﬁcient r2 > 0.5 with a signiﬁcant SNP
(deﬁned as a P value < 0.05) are ﬁltered out. From the
remaining independent SNPs, the statistic for each gene is
calculated as the mean of the single SNP statistics. To correct
for testing multiple SNPs within a gene, an empirical gene-
based P value is calculated on the basis of 10,000 replicates of
this procedure after random permutation of case–control
status, as the proportion of replicates with a statistic larger
than the one observed. To correct for testingmultiple genes, we
applied the false discovery rate method to the empirical gene-
based P values.
Genotype imputation of putative functional SNPs at
NEFL locus
As SNPs rs2979704, rs1059111, rs3761 were not included in
the Illumina HumanHap550 array, genotype imputation was
performed in the European American GWAS. Pre-phasing was
performed ﬁrst using SHAPEIT (16), followed by imputation
using 1000 Genomes data (phase I integrated release) and
IMPUTE2 (17). SNPs with minor allele frequency (MAF) <1%
and/or IMPUTE2-info quality score <0.8 were removed. To
account for imputation uncertainty, the remaining SNPs were
tested for association with neuroblastoma using the frequentist
test under the additive model with the "score" method imple-
mented in SNPTEST (18). A detailed description of genotype
imputation is reported in Supplementary Information.
SNP-gene expression correlation analysis in tumor
tissues and neuroblastoma cell lines
The inﬂuence of SNPs on NEFL gene expression was eval-
uated using data from genome-wide mRNA expression proﬁl-
ing (GSE3960) and SNP array genotyping (pha002845) in 51
neuroblastoma patients, and from qRT-PCR analysis in eight
neuroblastoma cell lines. A detailed description of the analysis
is reported in Supplementary Information.
In vitro functional analysis
A detailed description of the luciferase assay and other
experiments performed to evaluate the NEFL effect on neuro-
blastoma cell line phenotype is reported in Supplementary
Information.
Cell lines
The human SH-SY5Y, SK-N-AS, IMR-32, SK-N-BE2c, and
HEK293T/17 cell lines were obtained from the American Type
Culture Collection (respectively ATCC #CRL-2266, #CRL-2137,
#CCL-127, #CRL-2268, and #CRL-11268). SH-SY5Y, SK-N-AS,
and HEK293T/17 cell lines were grown in Dulbecco's Modiﬁed
Eagle Medium (DMEM; Sigma); the IMR32 cell line was grown
in Minimum Essential Medium Eagle (MEM; Sigma) and the
SK-N-BE2c cell linewas grown inDMEM/F12medium (Sigma).
Themediumwas supplementedwith 10%heat-inactivated FBS
(Sigma), 1 mmol/L L-glutamine, penicillin (100 U/mL), and
streptomycin (100 mg/mL; Invitrogen). The cells were cultured
at 37C, 5% CO2 in a humidiﬁed atmosphere. The cumulative
culture length of the cells was fewer than 6 months after
resuscitation. Early-passage cells were used for all experiments
and they were not reauthenticated.
Gene expression data for survival analysis and
association with neuroblastoma stages
NEFL normalized gene expression array data of three inde-
pendent sets of neuroblastoma patients (399 total) were down-
loaded from the website Oncogenomics (http://home.ccr.can-
cer.gov/oncology/oncogenomics/): (i) "Kahn dataset" com-
posed of 46 samples (Affymetrix Human Exon 1.0 ST Array,
GSE27608); (ii) "Oberthuer dataset" composed of 251 samples
(Agilent array Chip_10k_v1, E-TABM-38); and (iii) "Seeger
dataset" composed of 102 samples (Affymetrix HG-U133A and
HG-U133B array, GSE16254). Median centered normalization
was used for all gene expression data. This allowed us to
perform survival analysis on the three datasets combined.
However, to overcome any biases due to the different platforms
used in each dataset, we also performed ameta-analysis on the
summary statistics (see below). Analysis of association
between NEFL expression and neuroblastoma stages was
performed using normalized microarray data freely available
at the GEO database (GSE45547, GSE14880). Data for tumor
stages were available.
Statistical analysis
Hardy–Weinberg equilibrium was evaluated using the good-
ness-of-ﬁt x2 test in control subjects. For genotyped SNPs, two-
sided x2 tests were used to evaluate differences in the distribu-
tions of allele frequencies betweenall patients andcontrols. ORs
and 95% CIs were calculated to assess the relative disease risk
conferred by a speciﬁc allele. Combined analysiswas performed
using the weighted Z-scoremethod inMETAL based on sample
size, P value, and direction of effect in each study (19). The
Student t test was used to compare the differences in themRNA
expression levels. LD and haplotype analyses were performed
using the website tool SNAP v2.2 (http://www.broadinstitute.
org/mpg/snap/index.php; ref. 20) and Haploview v4.2 software
(21). qRT-PCR data were analyzed by the 2DCt method as
described in our previous article (22). To test the association of
gene expression levels with overall survival, individual gene
expression proﬁles were dichotomized by median split into
NEFL and Neuroblastoma
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"high" or "low" expression groups, and Kaplan–Meier survival
curves were plotted for each group. Cox regression analysis was
applied to calculate HR for meta-analysis. A test of heteroge-
neity of combined HRs was carried out using Cochran Q test
(signiﬁcant at P < 0.05) and Higgins I2 statistic. The I2 of >50%
were considered to represent signiﬁcant heterogeneity. Given
the absence of heterogeneity among studies (P > 0.1), a ﬁxed
effects generic inverse variance model was used. Meta-analysis
was performed using Review manager 5.0 (http://www.
cochrane.org).
Results
Biologically driven gene-based association analysis
Eight genes shown to be associated with neuroblastoma
differentiation (11) were tested for genetic associations with
neuroblastoma risk. The gene-based test performed on the
discovery set (2,101 cases and 4,202 controls) showed that the
two genes NEFL and SCG2 were signiﬁcantly associated with
neuroblastoma susceptibility (Table 1). However, NEFL had
eight SNPs,ﬁve ofwhichwere signiﬁcant, but only twoofwhich
were independently signiﬁcant based on an r2 threshold of 0.5;
whereas SCG2 had seven SNPs, but only one was signiﬁcant.
Prioritization of SNPs in SCG2 and NEFL
To select putative functional SNPs to be further validated in
the Italian cohort, we examined the genetic association and the
predicted biologic role of SNPs at both loci. At the SCG2 locus
(surrounding region  20 kb), only SNP rs4673067 resulted to
be signiﬁcant (data not shown). SNP function prediction
analysis using the Web tool SNPinfo Web Server (23) showed
no relevant function for this SNP and those in LD with it (r2 >
0.60; Supplementary Table S1). At the NEFL locus, three inter-
genic and two ﬂanking (in the 30 downstream and promoter
regions) polymorphisms were signiﬁcantly associated with
neuroblastoma (Table 2, Fig. 1A). SNP function prediction
analysis (23) showed that none of these ﬁve SNPs had putative
biologic function (data not shown). Thus, we carried out a
prioritization functional analysis on SNPs in LD (r2 > 0.60) with
the ﬁve typed SNPs (Supplementary Tables S2–S6). The results
indicated that three polymorphisms within the NEFL 30UTR
(rs3761, rs2979704, and rs1059111) had a potential biologic
effect (Table 2, Fig. 1A). Each of these SNPs was located in
evolutionary conserved regions and predicted to inﬂuence the
binding of diverse transcription factors and microRNAs (Sup-
plementary Tables S7–S9). In contrast, the analysis byUTRscan
(http://itbtools.ba.itb.cnr.it/utrscan) showed that none of the
abovementioned SNPs altered sequence characteristics of the
speciﬁc UTR motifs (such as: polyadenylation signal, AU rich
element, Selenocysteine Insertion Sequence and others
reported in the Supplementary Table S10). Taken together, in
silico data suggest that the functional role of SNPs located in
the 30 UTR of NEFL are likely due to alteration of miRNA
binding sites, enhancer elements, or both. Notably, rs3761 was
in LD with three signiﬁcant typed tag-SNPs (rs118727,
rs196830, and rs17830286), whereas rs2979704 and rs1059111
(in strong LD with each other; r2 ¼ 1; Supplementary Fig. S1)
were in LD with only one typed tag-SNP (rs11994014). To
further verify if other functional SNPs could be associated
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with neuroblastoma, we used the 1000 Genomes data to
impute all of the common variants (MAF > 0.05) across SCG2
and NEFL. No signiﬁcant association was found at the SCG2
locus (Supplementary Table S11). The rs3761 SNP in NEFL
resulted to be the strongest signiﬁcantly associated with
neuroblastoma. Other two SNPs (rs62503767 and rs62503769)
were signiﬁcant (Supplementary Table S11) but no relevant
biologic function was predicted (data not shown). Together,
these data led us to exclude SCG2 SNPs from further analyses
and to focus our attention on NEFL SNPs.
Replication study
We genotyped and tested for association in 459 neuroblas-
toma patients and 809 controls of Italian origin two tag-SNPs
(rs196830, the most signiﬁcant among the three tag-SNPs, and
rs11994014), the three prioritized SNPs (rs3761, rs2979704, and
rs1059111), in addition to the signiﬁcant typed SNP not in LD
with other SNPs (rs169061; Table 3). Only the tag-SNP
rs11994014 and the linked functional SNPs rs2979704 and
rs1059111 conﬁrmed the associations with neuroblastoma
(Table 3). Speciﬁcally, the minor alleles rs11994014-A,
rs2979704-C, and rs1059111-A were associated with a
decreased risk of neuroblastoma (Pcombined ¼ 0.0050; OR,
0.88; 95% CI, 0.81–0.96; Pcombined ¼ 0.0072; OR, 0.87; 95% CI,
0.78–0.96; Pcombined¼ 0.0049; OR, 0.86; 95% CI, 0.77–0.95). All of
these SNP alleles were associated with the favorable clinical
parameter age at diagnosis < 18 months in the European
American cohort (Supplementary Table S12) but not in the
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Italian cohort (Supplementary Table S13). This may be due to
the relatively low number of Italian cases in the clinical
subgroups. We found no signiﬁcant correlation between the
associated SNPs and other clinical covariates such as risk
group, INSS stage, and MYCN status.
Functional analysis of signiﬁcant SNPs
To investigate if the neuroblastoma-associated SNPs have a
cis-effect on NEFL, we tested for SNP-gene expression associa-
tions at tag-SNP rs11994014 and prioritized SNP rs1059111
using different approaches. For these analyses, we chose the
putative functional polymorphism rs1059111 because it
showed the highest scores for potential regulation and con-
servation and it is predicted to alter miRNA binding sites
(Table 2, Fig. 1A and Supplementary Table S8). Moreover, an
additional analysis using HaploReg v2 (24) showed that
rs1059111 resides within a DNase hypersensitive area in the
SK-N-BE2c neuroblastoma cell line, the highest conserved
region among the regions of other SNPs (Fig. 1A) and is
predicted to alter the regulatory motifs of the transcriptional
factor neuron restrictive silencer factor (NRSF; Supplementary
Table S9). Interestingly, the NEFL gene expression increased
when we silenced NRSF in two neuroblastoma cell lines (SH-
SY5Y and SK-N-BE2c; Supplementary Fig. S2A–S2D). These
ﬁndings strengthen the role ofNRSF as oncogene and repressor
of differentiation in neuroblastoma (25, 26) and provide evi-
dences to support the role of NEFL in neuroblastoma differ-
entiation. The analysis of gene expression variation using
genome-wide expression and SNP arrays of neuroblastoma
tumors demonstrated that both SNPs affect expression of
NEFL. In particular, the presence of the protective alleles (A
and A) for SNPs rs11994014 and rs1059111 signiﬁcantly cor-
related with increased NEFL mRNA expression (Fig. 1B). A
qRT-PCR gene expression analysis was performed in neuro-
blastoma cell lines. The mRNA expression of NEFL was signif-
icantly higher in neuroblastoma cell lines heterozygous at
rs1059111 (TA; Fig. 1C). Only a trend toward association
between high mRNA levels and presence of the protective
allele A was observed for rs11994014 without reaching the
threshold for statistical signiﬁcance (Fig. 1C). These results
were conﬁrmed using freely available data (http://www.broad-
institute.org/ccle) on gene expression and SNP arrays for 16
neuroblastoma cell lines (Supplementary Fig. S3A) and for 198
lymphoblastoid cell lines (Supplementary Fig. S3B). The cor-
relation of SNP rs1059111 with NEFL expression was validated
byWestern blotting (Fig. 1D). Induction of 30UTR activity of the
construct containing rs2979704-C and rs1059111-A alleles was
higher than that of the construct containing T alleles as
assessed by luciferase report gene assay (Fig. 1E). Finally,NEFL
mRNA abundance from clones containing the rs2979704-C and
rs1059111-A alleles after actinomycin-D addition was signiﬁ-
cantly higher than expression from clones containing the T
alleles (Fig. 1F). Together, these data indicate that theA allele of
SNP rs1059111 in 30UTR of NEFL confers a decreased neuro-
blastoma risk and induces gene overexpression in neuroblas-
toma tumors compared with the alternative allele T. This is
probably due to the alteration ofmiRNA binding site, enhancer
elements, or both. Further investigations are needed to address
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this issue.Moreover, transient overexpression ofNEFL resulted
in signiﬁcant growth inhibition in neuroblastoma cell hetero-
zygous for the rs1059111 protective A allele that had highNEFL
expression (Fig. 2A). In the cell lines homozygous for the risk T
allele that had low NEFL expression, the growth inhibition was
less marked (Fig. 2B and C). The same results were conﬁrmed
in cell lines with stable expression of NEFL (Fig. 2E and D).
These data suggest that the protective alleles are associated
with growth disadvantage through increased NEFL expression.
We have also evaluated cell growth and invasion after NEFL
silencing in two TA genotype cell lines (SH-SY5Y and SK-N-
BE2c). We observed no effect on cell growth, but increased cell
invasion was evident in both the cell lines (Supplementary Fig.
S4A–S4C). We hypothesize that decrease of cell growth
observed in cell lines with enforced expression of NEFL (Fig.
2A) is probably due to the effect of cell conversion into more
differentiated status.
Functional analysis of NEFL overexpression
To unravel NEFL contribution to neuroblastoma tumori-
genesis and progression, we generated NEFL stable clones in
two cell lines heterozygous for the protective minor allele (SH-
SY5Y) and homozygous for the risk major allele (SK-N-AS). SH-
SY5Y NEFL stable clones showed an enhanced differentiated
phenotype as assessed by increased neurites length, whereas
SK-N-AS NEFL stable clones became ﬂatter and larger than
control pcDNA clones (Fig. 3A and B). Moreover, the expres-
sion of neuronal differentiation markers is also enhanced by
NEFL overexpression in SH-SY5Y cells but not in SK-N-AS cells
(Fig. 3C). The analysis using freely available data (http://www.
broadinstitute.org/ccle) showed that three of these neuronal
markers were upregulated in neuroblastoma cell lines with the
protective allele and high level of NEFL basal expression
(Supplementary Fig. S5). In both NEFL overexpressing cell
lines, we observed a reduced proliferation as assessed by the
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PCNAWestern blotting analysis (Fig. 3D) but not an increased
caspase activity (data not shown). In an experiment of anchor-
age-independent growth in soft agar, we observed that NEFL
overexpression in SH-SY5Y cells impaired the growth ability
(Fig. 3E). In contrast, SK-N-AS cells showed no or very little
anchorage-independent growth in soft agar (data not shown).
NEFL overexpression in SH-SY5Y (Fig. 3F) and SK-N-AS (Fig.
3G) cells impaired the migratory ability in invasion assay.
These ﬁndings suggest that different phenotypic effect of the
overexpression might be due to underlying genotype and basal
NEFL expression in the two neuroblastoma cell lines.
Correlation analysis of NEFL gene expression with
clinical outcome
To examine the relevance of NEFL in patients, we investi-
gated if gene expression was associated with clinical outcome.
Analysis of three publicly available gene expression array data
of neuroblastoma showed that high NEFL expression is asso-
ciated with better survival (Fig. 4A–D, Pcombined¼ 0.04; Fig. 4E,
Pmeta-analysis ¼ 0.03; HR, 0.68; 95% CI, 0.48–0.97), well-differen-
tiated tumors (Fig. 4F, P¼ 0.002), and favorable stages (Fig. 4G,
stage I vs. stage IV; P¼ 2.3  104). No signiﬁcant association
was found between NEFL expression and the prognostic vari-
ables age at diagnosis, MYCN status, and risk group (data not
shown).
Discussion
Further investigation of eight genes that we previously
identiﬁed as being essential mediators of neuroblastoma dif-
ferentiation has identiﬁed NEFL as a susceptibility gene. Par-
ticularly, the minor allele of SNP rs1059111 correlates with
increased levels of NEFL and confers protection against neu-
roblastoma development, and is associatedwith amore benign
phenotype in those that do develop. In silico analyses suggest
that the SNP rs1059111 may alter the binding site of micro-
RNAs and transcription factors. However, in vitro validation
experiments of these data need to be performed in future
pcDNA# NEFL#
SK
-N
-A
S
SH
-S
Y5
Y 120
100
80
60
40
20
0
4
3
2
1
0
5
4
3
2
1
0
SH
SY
5Y
 n
eu
rit
e 
le
ng
th
 (μ
m
o
l/L
)
SH
-S
Y5
Y 
co
lo
ny
 n
u
m
be
r
SK
-N
-A
S-
in
va
di
ng
 c
el
ls
SH
-S
Y5
Y-
in
va
di
ng
 c
el
ls
PC
NA
 p
ro
te
in
 (O
D)
Fo
ld
 m
RN
A 
in
du
ct
io
n
pcD
NA
#
TU
J-1
MA
P-2
NE
ST
IN
TA
U
NE
FL
#
SH-SY5Y_pcDNA#
SH-SY5Y_NEFL#
SK-N-AS_pcDNA#
SK-N-AS_NEFL#
pc
DN
A#
pcD
NA
#
NE
FL
#
pc
DN
A#
NE
FL
#
pcD
NA
NE
FL
#
N
EF
L#
N
EF
L#
pc
DN
A#
SH-SY5Y SK-N-AS
Anti_PCNA
Anti_β-Actin
3,000
2,500
2,000
1,500
1,000
500
0
1,000
800
600
400
200
0
1,000
800
600
400
200
0
A B C
D
E F G
Figure 3. Different phenotypic effect of the NEFL overexpression in two neuroblastoma cells with protective and risk genotype for the SNP rs1059111.
A, SH-SY5Y (TA genotype) NEFL-overexpressing stable clones show longer neurites processes than pcDNA control cells, whereas SK-N-AS (TT genotype)
NEFL-overexpressing stable clones become ﬂatter. B, neurites length in SH-SY5Y cell clones were measured from the cell body to the furthest tip
of the process using LAS/AF tool (Leica Microsystems). C, the expression of neuronal differentiating markers is enhanced in SH-SY5Y NEFL stable clones,
whereas it does not change in SK-N-AS NEFL stable clones, as shown by qRT-PCR. D, the expression of PCNA is decreased in NEFL stable clones in
both cell lines. E, NEFL overexpression impairs the growth in soft agar of SH-SY5Y stable clones as shown by a decreased number of colonies with
respect to pcDNA cells. NEFL impairs the number of invading cells in two-dimensional invasion assay in SH-SY5Y (F) and SK-N-AS (G) stable clones.
The experiments were performed in three diverse clones for each experimental point and the shown results are representative of the mean among the
different clones. OD, optical density.
Capasso et al.
Cancer Res; 74(23) December 1, 2014 Cancer Research6920
on December 5, 2014. © 2014 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Published OnlineFirst October 13, 2014; DOI: 10.1158/0008-5472.CAN-14-0431 
studies. Forced overexpression of NEFL enhanced cellular
differentiation in cells with the protective allele and basal
NEFL expression, but had little effect on cells with the risk
genotype and undetectable basalNEFL expression. Silencing of
NEFL in cells with the protective allele did not affect cell
proliferation but induced cell invasion. Here, we present
preliminary data providing evidence that NEFL expression
sustains differentiated phenotype, impairs soft agar growth
and proliferation in cells with the protective allele, whereas
impairs invasiveness and proliferation in cells homozygous for
the riskmajor allele. Accordingly, highNEFLmRNA expression
levels correlate with well-differentiated tumors and show
association with a better clinical outcome. This suggests a
dual function for NEFL: suppressing cancer initiation and also
cancer progression. Taken together, these data provide direct
evidence that a functional DNA variant in the 30UTR region of
NEFL inﬂuences neuroblastoma susceptibility and that low
expression of NEFL plays a role in malignant neuroblastic
transformation and disease progression, likely by disrupting
a normal neuronal differentiation program.
Figure 4. NEFL expression is
associatedwith good outcomeand
favorable neuroblastoma stages.
A–C, Kaplan–Meier analysis
using published array data
(Oncogenomics laboratory Web
tool). D, Kaplan–Meier analysis
using combined array data from the
three independent sets. E, meta-
analysis of HRs from the Cox
regression analysis of each
dataset. F and G, changes in
expression for NEFL in
ganglioneuroblastoma (GNB) and
ganglioneuroma (GN; F) and in
favorable stage using published
array data (GEO database; G).
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The NEFL gene encodes a type IV intermediate ﬁlament
heteropolymer that functionally maintains the neuronal
caliber and plays an important role in the intracellular
transport of neurotransmitters to axons and dendrites
(27). Mutations in NEFL cause one of the most severe
Charcot–Marie–Tooth disease phenotypes (28). Recently,
several studies have proposed NEFL as a tumor-suppressor
gene. Indeed, deletions of the chromosomal region 8p21,
where NEFL is located, have been found in different cancer
diseases such as prostate cancer (29–32), breast cancer (33–
35), colorectal cancer (36, 37), hepatocellular carcinoma
(38), and squamous cell carcinoma of the head and neck
(HNSCC; refs. 39, 40). Very recently, Chen and colleagues
have demonstrated that in HNSCC, NEFL protein is phys-
ically associated with tuberous sclerosis 1 (TSC1), and NEFL
downregulation by methylation process leads to functional
activation of mTOR pathway and consequentially confers
cisplatin resistance (41). The same research group also
showed that NEFL expression induces cancer cell apoptosis
and inhibits invasion in HNSCC cell lines (42). In agreement
with our ﬁndings, literature data strongly suggest that NEFL
might play a critical role in suppressing cancer initiation
and/or progression.
Neuroblastoma can be considered a malignancy due, at
least in part, to a loss of normal differentiation pathways
(12). Here, we suggest that downregulation of NEFL expres-
sion through constitutional DNA variation can predispose to
neuroblastoma development because low levels of NEFL can
affect the normal differentiation of sympathetic neurons. As
a consequence, the derivate immature cells may be suscep-
tible to secondary mutations that could ultimately lead to
neuroblastoma. In agreement with our hypothesis, two
research groups have already reported that genetic events
affecting the dosage of neuronal prodifferentiation genes
might lead to the accumulation of a cell population that is
unable to differentiate and can thus acquire the necessary
transforming genetic or epigenetic aberrations (43, 44). Wu
and colleagues have demonstrated that genes involved in
brain development and neuronal differentiation, such as
BMP4, POU4F3, GDNF, OTX2, NEFM, CNTN4, OTP, SIM1, FYN,
EN1, CHAT, GSX2, NKX6-1, PAX6, RAX, and DLX2, are strongly
enriched among genes frequently methylated in astrocyto-
mas (44). Pei and colleagues showed that a reduced dosage
of PHOX2B during development, through either a heterozy-
gous deletion or dominant-negative mutation, imposes a
block in the differentiation of sympathetic neuronal pre-
cursors, resulting in a cell population that is likely to be
susceptible to secondary transforming events (43). Even if
our ﬁndings suggest that low NEFL expression can play a
role in tumor initiation by affecting neuronal differentiation,
we do not exclude that NEFL can be involved in different
molecular mechanisms whose alteration can contribute to
tumor initiation and progression in neuroblastoma. Indeed,
NEFL has been found to interact with proteins such as
TRIM2 (45) and TSC1 (41) with high relevance in cancer
and that participate in various important cellular processes.
Interestingly, another gene mutated in Charcot–Marie–
Tooth disease, KIF1B (28), seems to act as a haploinsufﬁ-
cient tumor suppressor, and its downregulation might
potentially contribute to tumorigenesis of cancers, includ-
ing neuroblastoma (46, 47). These data strengthen the
hypothesis that alteration in normal expression of genes
involved in neuronal development can induce neuroblasto-
ma carcinogenesis.
In summary, we have identiﬁed NEFL as a novel suscepti-
bility gene for neuroblastoma starting from the analysis of a set
of genes involved in neuronal differentiation and using data
from a neuroblastoma GWAS. Our results support the hypoth-
esis that downregulation of NEFL gene expression through
functional hereditable DNA variation can contribute to malig-
nant transformation of sympathetic progenitor cells. More-
over, we provide evidence that NEFL expression enhances
differentiation and impairs cancer progression in neuroblas-
toma cell lines. This study has demonstrated that a hypothesis-
drivenGWAS follow-up study is a useful strategy for identifying
novel disease susceptibility genes and that genetic and func-
tional datasets can be merged to maximize discovery efforts.
GWASs so far have led to substantial advances in our under-
standing of the role of common variation in complex disease
and have identiﬁed previously unknown pathogenic pathways
in neuroblastoma (4–8, 48) and other disorders (49). However,
many disease-associated variants remain unknown or func-
tionally uncharacterized and biologic implications of risk-
associated variants in pathogenesis are largely unknown
(49). The methodologic approach here presented might be a
useful tool to overcome some of the limits emerged from
GWAS studies.
Disclosure of Potential Conﬂicts of Interest
No potential conﬂicts of interest were disclosed.
Authors' Contributions
Conception and design: M. Capasso, H. Hakonarson, A. Iolascon, J.M. Maris
Development of methodology: F. Cimmino, F. Totaro, L. Pezone, J.M. Maris
Acquisition of data (provided animals, acquired and managed patients,
provided facilities, etc.): H. Hakonarson, J.M. Maris
Analysis and interpretation of data (e.g., statistical analysis, biostatistics,
computational analysis): M. Capasso, S. Diskin, G. Acierno, G. Petrosino,
L. McDaniel, H. Hakonarson, M. Devoto, J.M. Maris
Writing, review, and/or revision of the manuscript: M. Capasso, S. Diskin,
H. Hakonarson, A. Iolascon, M. Devoto, J.M. Maris
Administrative, technical, or material support (i.e., reporting or orga-
nizing data, constructing databases): M. Diamond, J.M. Maris
Study supervision: J.M. Maris
Grant Support
This study was supported by grants from Associazione Italiana per la Ricerca
sul Cancro 10537 (M. Capasso), MIUR- FIRB Ricerca in Futuro RBFR08DWQ3
(M. Capasso), Fondazione Italiana per la Lotta al Neuroblastoma (M. Capasso),
and Associazione Oncologia Pediatrica e Neuroblastoma (M. Capasso). This
work was also supported in part by NIH Grants R01-CA124709 (J.M. Maris), 5P30
CA016520 (J.M. Maris), K99-CA151869 (S. Diskin), P30-HD026979 (M. Devoto),
the Giulio D'Angio Endowed Chair (J.M. Maris), the Alex's Lemonade Stand
Foundation (J.M. Maris), Andrew's Army Foundation (J.M. Maris), the PressOn
Foundation (J.M. Maris), Ali's Discovery Fund (J.M. Maris), and the Abramson
Family Cancer Research Institute (J.M. Maris).
The costs of publication of this article were defrayed in part by the payment of
page charges. This article must therefore be hereby marked advertisement in
accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received February 12, 2014; revised September 25, 2014; accepted September
30, 2014; published OnlineFirst October 13, 2014.
Capasso et al.
Cancer Res; 74(23) December 1, 2014 Cancer Research6922
on December 5, 2014. © 2014 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Published OnlineFirst October 13, 2014; DOI: 10.1158/0008-5472.CAN-14-0431 
References
1. Maris JM. Recent advances in neuroblastoma. N Engl J Med
2010;362:2202–11.
2. Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF,
et al. Identiﬁcation of ALK as a major familial neuroblastoma predis-
position gene. Nature 2008;455:930–5.
3. Capasso M, Diskin SJ. Genetics and genomics of neuroblastoma.
Cancer Treat Res 2010;155:65–84.
4. Maris JM, Mosse YP, Bradﬁeld JP, Hou C, Monni S, Scott RH, et al.
Chromosome 6p22 locus associated with clinically aggressive neu-
roblastoma. N Engl J Med 2008;358:2585–93.
5. Capasso M, Devoto M, Hou C, Asgharzadeh S, Glessner JT, Attiyeh
EF, et al. Common variations in BARD1 inﬂuence susceptibility to high-
risk neuroblastoma. Nat Genet 2009;41:718–23.
6. Wang K, Diskin SJ, Zhang H, Attiyeh EF, Winter C, Hou C, et al.
Integrative genomics identiﬁes LMO1 as a neuroblastoma oncogene.
Nature 2011;469:216–20.
7. Nguyen leB,DiskinSJ, CapassoM,WangK,DiamondMA,Glessner J,
et al. Phenotype restricted genome-wide association study using a
gene-centric approach identiﬁes three low-risk neuroblastoma sus-
ceptibility Loci. PLoS Genet 2011;7:e1002026.
8. Diskin SJ, CapassoM, SchneppRW, Cole KA, Attiyeh EF, HouC, et al.
Common variation at 6q16 within HACE1 and LIN28B inﬂuences
susceptibility to neuroblastoma. Nat Genet 2012;44:1126–30.
9. CapassoM,DiskinSJ, TotaroF, LongoL,DeMarianoM,RussoR, et al.
Replication of GWAS-identiﬁed neuroblastoma risk loci strengthens
the role of BARD1 and afﬁrms the cumulative effect of genetic varia-
tions on disease susceptibility. Carcinogenesis 2013;34:605–11.
10. Cantor RM, Lange K, Sinsheimer JS. Prioritizing GWAS results: A
review of statistical methods and recommendations for their applica-
tion. Am J Hum Genet 2010;86:6–22.
11. CimminoF, SpanoD,CapassoM, ZambranoN,RussoR, ZolloM, et al.
Comparative proteomic expression proﬁle in all-trans retinoic
acid differentiated neuroblastoma cell line. J Proteome Res 2007;6:
2550–64.
12. CheungNK, DyerMA. Neuroblastoma: developmental biology, cancer
genomics and immunotherapy. Nat Rev Cancer 2013;13:397–411.
13. Mao L, Ding J, ZhaY, Yang L,McCarthy BA, KingW, et al. HOXC9 links
cell-cycle exit andneuronal differentiation and is aprognosticmarker in
neuroblastoma. Cancer Res 2011;71:4314–24.
14. Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ,
van der Ploeg I, et al. Sequencing of neuroblastoma identiﬁes
chromothripsis and defects in neuritogenesis genes. Nature 2012;
483:589–93.
15. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D,
et al. PLINK: a tool set for whole-genome association and population-
based linkage analyses. Am J Hum Genet 2007;81:559–75.
16. Delaneau O, Zagury JF, Marchini J. Improved whole-chromosome
phasing for disease and population genetic studies. Nat Methods
2013;10:5–6.
17. Howie BN, Donnelly P, Marchini J. A ﬂexible and accurate genotype
imputation method for the next generation of genome-wide associa-
tion studies. PLoS Genet 2009;5:e1000529.
18. Marchini J, Howie B,Myers S,McVeanG, Donnelly P. A newmultipoint
method for genome-wide association studies by imputation of geno-
types. Nat Genet 2007;39:906–13.
19. WillerCJ, LiY, AbecasisGR.METAL: fast andefﬁcientmeta-analysis of
genomewide association scans. Bioinformatics 2010;26:2190–1.
20. Johnson AD, Handsaker RE, Pulit SL, Nizzari MM, O'Donnell CJ, de
Bakker PI. SNAP: aweb-based tool for identiﬁcation and annotation of
proxy SNPs using HapMap. Bioinformatics 2008;24:2938–9.
21. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visual-
ization of LD and haplotype maps. Bioinformatics 2005;21:263–5.
22. Capasso M, Avvisati RA, Piscopo C, Laforgia N, Raimondi F, de
Angelis F, et al. Cytokine gene polymorphisms in Italian preterm
infants: association between interleukin-10 -1082 G/A polymorphism
and respiratory distress syndrome. Pediatr Res 2007;61:313–7.
23. Xu Z, Taylor JA. SNPinfo: integrating GWAS and candidate gene
information into functional SNP selection for genetic association
studies. Nucleic Acids Res 2009;37:W600–5.
24. Ward LD, Kellis M. HaploReg: a resource for exploring chromatin
states, conservation, and regulatory motif alterations within sets of
genetically linked variants. Nucleic Acids Res 2012;40:D930–4.
25. Negrini S, Prada I, D'Alessandro R,Meldolesi J. REST: an oncogene or
a tumor suppressor? Trends Cell Biol 2013;23:289–95.
26. Singh A, Rokes C, Gireud M, Fletcher S, Baumgartner J, Fuller G, et al.
Retinoic acid induces REST degradation and neuronal differentiation
by modulating the expression of SCF(beta-TRCP) in neuroblastoma
cells. Cancer 2011;117:5189–202.
27. Leermakers FA, Zhulina EB. How the projection domains of NF-L and
alpha-internexin determine the conformations of NF-M and NF-H in
neuroﬁlaments. Eur Biophys J 2010;39:1323–34.
28. Gentil BJ, Cooper L. Molecular basis of axonal dysfunction and trafﬁc
impairments in CMT. Brain Res Bull 2012;88:444–53.
29. Bova GS, Carter BS, Bussemakers MJ, Emi M, Fujiwara Y, Kyprianou
N, et al. Homozygous deletion and frequent allelic loss of chromosome
8p22 loci in human prostate cancer. Cancer Res 1993;53:3869–73.
30. MacGrogan D, Levy A, Bostwick D, Wagner M, Wells D, Bookstein R.
Loss of chromosome arm 8p loci in prostate cancer: mapping by
quantitative allelic imbalance. Genes Chromosomes Cancer 1994;10:
151–9.
31. Kagan J, Stein J, Babaian RJ, Joe YS, Pisters LL, Glassman AB, et al.
Homozygous deletions at 8p22 and 8p21 in prostate cancer implicate
these regions as the sites for candidate tumor suppressor genes.
Oncogene 1995;11:2121–6.
32. Trapman J, Sleddens HF, van der Weiden MM, Dinjens WN, Konig JJ,
Schroder FH, et al. Loss of heterozygosity of chromosome 8 micro-
satellite loci implicates a candidate tumor suppressor gene between
the loci D8S87 and D8S133 in human prostate cancer. Cancer Res
1994;54:6061–4.
33. Seitz S, Werner S, Fischer J, Nothnagel A, Schlag PM, Scherneck S.
Reﬁned deletion mapping in sporadic breast cancer at chromosomal
region 8p12-p21 and association with clinicopathological parameters.
Eur J Cancer 2000;36:1507–13.
34. Yaremko ML, Kutza C, Lyzak J, Mick R, Recant WM, Westbrook CA.
Loss of heterozygosity from the short arm of chromosome 8 is
associated with invasive behavior in breast cancer. Genes Chromo-
somes Cancer 1996;16:189–95.
35. YaremkoML,RecantWM,WestbrookCA. Loss of heterozygosity from
the short arm of chromosome 8 is an early event in breast cancers.
Genes Chromosomes Cancer 1995;13:186–91.
36. Yaremko ML, Wasylyshyn ML, Paulus KL, Michelassi F, Westbrook
CA. Deletionmapping reveals two regions of chromosome 8 allele loss
in colorectal carcinomas. Genes Chromosomes Cancer 1994;10:1–6.
37. Lerebours F, Olschwang S, Thuille B, Schmitz A, Fouchet P, Laurent-
Puig P, et al. Deletion mapping of the tumor suppressor locus involved
in colorectal cancer on chromosome band 8p21. Genes Chromo-
somes Cancer 1999;25:147–53.
38. Becker SA, Zhou YZ, Slagle BL. Frequent loss of chromosome 8p in
hepatitis B virus-positive hepatocellular carcinomas from China. Can-
cer Res 1996;56:5092–7.
39. CoonSW,SaveraAT, ZarboRJ, BenningerMS,ChaseGA,Rybicki BA,
et al. Prognostic implications of loss of heterozygosity at 8p21 and
9p21 in head and neck squamous cell carcinoma. Int J Cancer
2004;111:206–12.
40. el-Naggar AK, Hurr K, Batsakis JG, Luna MA, Goepfert H, Huff V.
Sequential loss of heterozygosity atmicrosatellitemotifs in preinvasive
and invasive head and neck squamous carcinoma. Cancer Res
1995;55:2656–9.
41. Chen B, Chen J, House MG, Cullen KJ, Nephew KP, Guo Z. Role of
neuroﬁlament light polypeptide in head and neck cancer chemoresis-
tance. Mol Cancer Res 2012;10:305–15.
42. Huang Z, Zhuo Y, Shen Z,Wang Y,Wang L, Li H, et al. The role of NEFL
in cell growth and invasion in head and neck squamous cell carcinoma
cell lines. J Oral Pathol Med 2014;43:191–8.
43. Pei D, Luther W, Wang W, Paw BH, Stewart RA, George RE. Distinct
neuroblastoma-associated alterations of PHOX2B impair sympathetic
neuronal differentiation in zebraﬁsh models. PLoS Genet 2013;9:
e1003533.
www.aacrjournals.org Cancer Res; 74(23) December 1, 2014 6923
NEFL and Neuroblastoma
on December 5, 2014. © 2014 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Published OnlineFirst October 13, 2014; DOI: 10.1158/0008-5472.CAN-14-0431 
44. Wu X, Rauch TA, Zhong X, Bennett WP, Latif F, Krex D, et al. CpG island
hypermethylation inhumanastrocytomas.CancerRes2010;70:2718–27.
45. Balastik M, Ferraguti F, Pires-da Silva A, Lee TH, Alvarez-Bolado G, Lu
KP, et al. Deﬁciency in ubiquitin ligase TRIM2 causes accumulation of
neuroﬁlament light chain and neurodegeneration. Proc Natl Acad Sci
U S A 2008;105:12016–21.
46. Munirajan AK, Ando K, Mukai A, Takahashi M, Suenaga Y, Ohira M,
et al. KIF1Bbeta functions as a haploinsufﬁcient tumor suppressor
gene mapped to chromosome 1p36.2 by inducing apoptotic cell
death. J Biol Chem 2008;283:24426–34.
47. Schlisio S, Kenchappa RS, Vredeveld LC, George RE, Stewart R,
Greulich H, et al. The kinesin KIF1Bbeta acts downstream from EglN3
to induce apoptosis and is a potential 1p36 tumor suppressor. Genes
Dev 2008;22:884–93.
48. Bosse KR, Diskin SJ, Cole KA,Wood AC, Schnepp RW, Norris G, et al.
Common variation at BARD1 results in the expression of an oncogenic
isoform that inﬂuences neuroblastoma susceptibility and oncogenic-
ity. Cancer Res 2012;72:2068–78.
49. Manolio TA. Bringing genome-wide association ﬁndings into clinical
use. Nat Rev Genet 2013;14:549–58.
Cancer Res; 74(23) December 1, 2014 Cancer Research6924
Capasso et al.
on December 5, 2014. © 2014 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Published OnlineFirst October 13, 2014; DOI: 10.1158/0008-5472.CAN-14-0431 
2014;74:6913-6924. Published OnlineFirst October 13, 2014.Cancer Res 
  
Mario Capasso, Sharon Diskin, Flora Cimmino, et al. 
  
Neuroblastoma Risk
 Influence Gene Expression andNEFLCommon Genetic Variants in 
  
Updated version
  
 10.1158/0008-5472.CAN-14-0431doi:
Access the most recent version of this article at:
  
Material
Supplementary
  
 http://cancerres.aacrjournals.org/content/suppl/2014/10/11/0008-5472.CAN-14-0431.DC1.html
Access the most recent supplemental material at:
  
  
  
  
  
Cited Articles
  
 http://cancerres.aacrjournals.org/content/74/23/6913.full.html#ref-list-1
This article cites by 49 articles, 17 of which you can access for free at:
  
  
  
E-mail alerts  related to this article or journal.Sign up to receive free email-alerts
  
Subscriptions
Reprints and 
  
.pubs@aacr.org
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at
  
Permissions
  
.permissions@aacr.org
To request permission to re-use all or part of this article, contact the AACR Publications Department at
on December 5, 2014. © 2014 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Published OnlineFirst October 13, 2014; DOI: 10.1158/0008-5472.CAN-14-0431 
